CoChat

Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model

CHOI, IN YOUNG, KIM, JUNG KUK, LEE, JONG SUK, PARK, EUNJIN, KIM, YOUNG HOON, JUNG, SUNG YOUB, KIM, SUN JIN · 2018 · Diabetes
Cited by 18

The DOI matches its Crossref record.

Abstract

Nonalcoholic steatohepatitis (NASH), a potential consequence of NAFLD, may lead to end stage liver disease including cirrhosis and hepatocellular carcinoma. Despite its severity and prevalence, NASH currently lacks effective treatment. In this respect, we developed a novel long-acting, GLP-1/GIP/Glucagon triple agonist, HM15211. With a unique activity profile, HM15211 could provide synergistic benefits on body weight loss and lipid profile improvement while avoiding hyperglycemic risk. Previously, we showed that HM15211 exerts potent reductions in body weight and hepatic TG (triglycerides) in DIO mice, and showed a liver preferential distribution, suggesting HM15211 as a potential treatment for NASH. Here, we evaluated the effect of HM15211 in NASH and fibrosis using MCD-diet mice with various disease induction periods. In MCD-diet mice (6 weeks induction), HM15211 treatment led to significant decrease in hepatic TG (-82.6% vs. vehicle) and TBARS (oxidative stress marker, -60.7% vs. vehicle), which coincided with significant reduction in ALT and bilirubin. Time course MRI/MRS imaging further confirmed the progressive steatosis resolution by HM15211. Furthermore, histopathological analysis indicated that HM15211 significantly reduced hepatic inflammatory gene expression and NAFLD activity score (1.3 for HM15211, 3.4 for liraglutide, and 2.7 for vehicle). To further evaluate the therapeutic potential in fibrosis, MCD-diet mice was used for an extended period (10 weeks induction) to achieve overt liver fibrosis. In line with NASH improvement, HM15211 successfully resolved liver fibrosis as demonstrated in histological evaluation. Histological improvements were accompanied by a remarkable decrease in disease biomarkers including hepatic hydroxyproline. Based on these observations, HM15211 may offer a therapeutic potential for NASH and fibrosis as well as obesity. Disclosure: I. Choi: Employee; Self; Hanmi Pharmaceutical. Stock/Shareholder; Self; Hanmi Pharmaceutical. J. Kim: Employee; Self; Hanmi Pharmaceutical. Stock/Shareholder; Self; Hanmi Pharmaceutical. J. Lee: Employee; Self; Hanmi Pharmaceutical. Stock/Shareholder; Self; Hanmi Pharmaceutical. E. Park: Employee; Self; Hanmi Pharmaceutical. Y. Kim: Employee; Self; Hanmi Pharmaceutical. S. Jung: None. S. Kim: Employee; Self; Hanmi Pharmaceutical. Stock/Shareholder; Self; Hanmi Pharmaceutical.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db18-1106-p

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 18

Metadata

Authors
CHOI, I. Y., KIM, J. K., LEE, J. S., PARK, E., KIM, Y. H., JUNG, S. Y., & KIM, S. J.
Venue
Diabetes
Published
2018-07-01
Volume
67
Issue
Supplement_1
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2809236699
Cited by
18
References
0
FWCI
2.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model. https://app.cochat.ai/papers/10.2337/db18-1106-p
The paper
CHOI, I. Y., KIM, J. K., LEE, J. S., PARK, E., KIM, Y. H., JUNG, S. Y., & KIM, S. J. (2018). Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model. Diabetes. https://doi.org/10.2337/db18-1106-p

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.